Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 383-393

  Oishi, Yoshichika ^a   Watanabe, Yoshiyuki ^a,b,c   Yoshida, Yoshihito ^a   Sato, Yoshinori ^a   Hiraishi, Tetsuya ^a   Oikawa, Ritsuko ^a   Maehata, Tadateru ^a   Suzuki, Hiromu ^b   Toyota, Minoru ^b   Niwa, Hirohumi ^a   Suzuki, Michihiro ^a   Itoh, Fumio ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c Kawasaki Rinkou General Hospital   (Japan)

Author keywords

DNA methylation; Gastric cancer; Gastric washes; Sox17

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; TRANSCRIPTION FACTOR SOX17; AZACITIDINE; DRUG DERIVATIVE; SOX17 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

AGED; ARTICLE; CANCER GROWTH; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG MECHANISM; EARLY CANCER; ENDOSCOPIC SURGERY; FEMALE; GASTROSCOPY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOX17 GENE; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH LAVAGE; VALIDATION PROCESS; DISEASE COURSE; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MIDDLE AGED; RISK; STOMACH TUMOR; TUMOR CELL LINE;

AGED; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RISK; SOXF TRANSCRIPTION FACTORS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860273603     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0278-y     Document Type: Article

References (48)

1. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305-15.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-43.
4. Denk H, Tappeiner G, Davidovits A, Holzner HJ. The carcinoembryonic antigen (CEA) in carcinomata of the stomach. Virchows Arch A Pathol Pathol Anat. 1973;360:339-47.
5. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957-71.
6. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology. 2009;136:2149-58.
7. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A. 2003;100:12253-8.
8. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5:121-5.
9. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Kato Y, Yanagisawa A, Nakamura Y. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res. 1992;52:3231-3.
10. Nanus DM, Kelsen DP, Mentle IR, Altorki N, Albino AP. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology. 1990;98:955-60.
11. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol. 1995;176:249-58.
12. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253-66.
13. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-93.
14. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 2005;5:223-31.
15. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA, Picchi MA. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005;11:6505-11.
16. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy III PC, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111-7.
17. Suzuki H, Toyota M, Sato H, Sonoda T, Sakauchi F, Mori M. Roles and causes of abnormal DNA methylation in gastrointestinal cancers. Asian Pac J Cancer Prev. 2006;7:177-85.
18. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, Tokino T. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein- Barr virus. Cancer. 2006;106:1467-79.
19. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology. 2005;129:1121-4.
20. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000;97:710-5.
21. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59:5438-42.
22. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-6.
23. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330-8.
24. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;7:2.
25. Kim SK, Jang HR, Kim JH, Noh SM, Song KS, Kim MR, Kim SY, Yeom YI, Kim NS, Yoo HS, Kim YS. The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. Biochem Biophys Res Commun. 2006;349:1032-40.
26. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JP. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007;3:2023-36.
27. Estecio MR, Yan PS, Huang TH, Issa JP. Methylated CpG island amplification and microarray (MCAM) for high-throughput analysis of DNA methylation. CSH Protoc 2008;2008:db.
28. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 2007;17:1529-36.
29. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112:1366-73.
30. Okamoto Y, Sawaki A, Ito S, Nishida T, Takahashi T, Toyota M, Suzuki H, Shinomura Y, Takeuchi I, Shinjo K, An B, Ito H, Yamao K, Fujii M, Murakami H, Osada H, Kataoka H, Joh T, Sekido Y, Kondo Y. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut 2011; doi:10.1136/ gut.2011.241034.
31. Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, Nishikawa N, Watanabe Y, Sasaki Y, Abe T, Yamamoto E, Tarasawa I, Sonoda T, Mori M, Imai K, Shinomura Y, Tokino T. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2007;98:88-95.
32. Kikuchi T, Itoh F, Toyota M, Suzuki H, Yamamoto H, Fujita M, Hosokawa M, Imai K. Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer. 2002;97:272-7.
33. Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, Yamamoto E, Nojima M, Fujikane T, Sasaki Y, Yamashita T, Watanabe Y, Hiratsuka H, Hirata K, Itoh F, Imai K, Shinomura Y, Tokino T. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis. 2008;29:1312-8.
34. Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, Ueno M, Takahashi F, Kusano M, Mita H, Yanagihara K, Endo T, Hinoda Y, Tokino T, Imai K. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res. 2005;11:1021-7.
35. Nojima M, Suzuki H, Toyota M,Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 2007;26:4699-713.
36. Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res. 2003;9:6410-8.
37. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 2003;63:8606-13.
38. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, Hinoda Y, Tokino T, Imai K. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol. 2004;25:134-40.
39. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res. 2007;13:4786-94.
40. Watanabe Y, Kato N, Maehata T, Okamoto M, Tsuda T, Hattori S, Yamauchi S, Fujita K, Baba S, Nakaya S, Inaba H, Kitajima S, Suzuki M, Niwa H, Itoh F. Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol. 2006;21:1675-80.
41. Ono H, Hasuike N, Inui T, Takizawa K, Ikehara H, Yamaguchi Y, Otake Y,Matsubayashi H. Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer. 2008;11:47-52.
42. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999;59:2307-12.
43. Sano T. Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. Gan To Kagaku Ryoho. 2010;37:582-6.
44. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, Piao YS, Yoshimoto T, Minamoto T, Kotani H, Taketo MM, Oshima M. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology. 2009;137:1346-57.
45. Toyota M, Issa JP. The role of DNA hypermethylation in human neoplasia. Electrophoresis. 2000;21:329-33.
46. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol. 1999;9:349-57.
47. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573-7.
48. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van NL, Herman JG, Schuebel KE, Watkins DN, Ahuja N, Baylin SB. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008;68:2764-72.